Results 41 to 50 of about 4,744 (194)

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events

Clinical and Translational Science, 2021
Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not been widely implemented in North America and most studies of pretreatment ...
Theodore J. Wigle, Brandi L. Povitz, Samantha Medwid, Wendy A. Teft, Robin M. Legan, John Lenehan, Stephanie Nevison, Veera Panuganty, Denise Keller, Jaymie Mailloux, Victoria Siebring, Sisira Sarma, Yun‐hee Choi, Stephen Welch, Eric Winquist, Ute I. Schwarz, Richard B. Kim   +16 more
doaj   +1 more source

Pharmacogenomic tests in Oncology - finding the right dose

Brazilian Journal of Oncology, 2021
A pharmacogenetics/genomics (PGx) anticancer drug testing program is being developed by Kurtz and his group at the Brazilian National Cancer Institute (INCA).
Jeziel Basso, Gilberto Schwartsmann
doaj   +1 more source

Analysis of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation [PDF]

Терапевтический архив, 2020
Aim. To study the peculiarities of carrying clinically significant allelic variants of TPMT and DPYD genes associated with the response to drug therapy in cancer practice among 9 ethnic groups of the Russian Federation. Materials and methods.
K. B. Mirzaev, D. S. Fedorinov, K. A. Akmalova, Sh. P. Abdullaev, A. A. Kachanova, Zh. A. Sozaeva, E. A. Grishina, G. N. Shuev, E. Yu. Kitaeva, V. V. Shprakh, S. Sh. Suleymanov, L. Z. Bolieva, M. S-H. Sozaeva, S. M. Zhuchkova, N. E. Gimaldinova, E. E. Sidukova, I. S. Burashnikova, A. A. Shikaleva, K. G. Zabudskaya, D. A. Sychev   +19 more
doaj   +1 more source

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population [PDF]

, 2023
BackgroundIn 2020, the European Medicines Agency recommended testing patients for dihydropyrimidine dehydrogenase (DPD) deficiency before systemic treatment with fluoropyrimidines (FP).
Feddersen, S., Holm, H S, Bergmann, T K; id_orcid, Qvortrup, C., Qvortrup, C, Bergmann, T. K., Damkier, P; id_orcid, Pfeiffer, P., Ewertz, M., Pfeiffer, P; id_orcid, Paulsen, N H; id_orcid, Feddersen, S; id_orcid, Paulsen, N. H., Fruekilde, P. B.N., Damkier, P., Holm, H. S., Ewertz, M; id_orcid, Fruekilde, P B N   +17 more
core   +1 more source

DPYD Genotyping Recommendations

Journal of Molecular Diagnostics
The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays.
Pratt, Victoria M., Cavallari, Larisa H., Fulmer, Makenzie L., Gaedigk, Andrea, Hachad, Houda, Ji, Yuan, Kalman, Lisa V., Ly, Reynold C., Moyer, Ann M., Scott, Stuart A., Turner, Amy J., van Schaik, Ron H.N., Whirl-Carrillo, Michelle, Weck, Karen E.   +13 more
openaire   +5 more sources

Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms

World Journal of Surgical Oncology, 2020
Background Fluoropyrimidines and platinum are still widely used for colorectal cancer (CRC) management. Several studies have reported that mutations of dihydropyrimidine dehydrogenase (DPYD) and glutathione S-transferase pi-1 (GSTP1) polymorphisms are ...
Xunwei Deng, Jingyuan Hou, Qiaoting Deng, Zhixiong Zhong   +3 more
doaj   +1 more source

Frequency of dihydropyrimidine dehydrogenase and UDP-glucuronosyltransferase 1A1 variants in cancer patients requiring chemotherapy: A single-center study in southern India [PDF]

Journal of Clinical and Basic Research, 2023
Background: Cancer treatment using drugs metabolized by the enzymes dihydropyrimidine dehydrogenase (DPYD) and UDP-glucuronosyltransferase 1A1 (UGT1A1) results in adverse effects for some patients.
Kevin Nischay Gangavarapu, Nandini Shyamali Bora, Srinivas Maddali, Qurratulain Hasan   +3 more
doaj  

Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)

Brazilian Journal of Oncology, 2021
The implementation, current status and future perspectives of the pharmacogenetics/genomics (PGx) testing program developed at Instituto Nacional de Cancer (INCA) are presented. Initial selection of drug-gene pairs for PGx testing was based on clinically-
Guilherme Suarez-Kurtz
doaj   +1 more source

DPYD-geenitestaus kliinisessä käytössä

Duodecim, 2021
Peer ...
Saarenheimo, Jatta, Wahid, Nesna, Tornio, Aleksi, Ristamäki, Raija, Keinänen, Mauri, Niemi, Mikko, Turpeinen, Miia, Jekunen, Antti   +7 more
openaire   +5 more sources

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD). [PDF]

Pre-treatment genotyping of four well-characterized toxicity risk-variants in the dihydropyrimidine dehydrogenase gene (DPYD) has been widely implemented in Europe to prevent serious adverse effects in cancer patients treated with fluoropyrimidines ...
Angélique Sadlon, Largiadèr, Carlo R., Sara Bastian, Steven M. Offer, Sadlon, Angélique, Bastian, Sara, Ambrodji, Alisa, Hoch, Dennis, Dennis Hoch, Martin D. Berger, Offer, Steven M, Carlo R. Largiadèr, Amstutz, Ursula, Berger, Martin D., Ursula Amstutz, Alisa Ambrodji   +15 more
core   +2 more sources